Jpmorgan Chase & CO Autolus Therapeutics PLC Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,284,708 shares of AUTL stock, worth $2.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,284,708
Previous 523,700 145.31%
Holding current value
$2.94 Million
Previous $1.82 Million 155.93%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
BUY
$3.38 - $4.69 $2.57 Million - $3.57 Million
761,008 Added 145.31%
1,284,708 $4.66 Million
Q2 2024

Aug 12, 2024
BUY
$3.33 - $5.68 $1.31 Million - $2.24 Million
394,791 Added 306.26%
523,700 $1.82 Million
Q1 2024

May 10, 2024
BUY
$5.39 - $7.29 $546,955 - $739,760
101,476 Added 369.9%
128,909 $822,000
Q4 2023

Feb 12, 2024
BUY
$2.13 - $6.63 $58,206 - $181,178
27,327 Added 25780.19%
27,433 $176,000
Q3 2023

Nov 14, 2023
SELL
$2.32 - $3.36 $3,927 - $5,688
-1,693 Reduced 94.11%
106 $0
Q2 2023

Aug 11, 2023
SELL
$1.64 - $3.21 $720,330 - $1.41 Million
-439,226 Reduced 99.59%
1,799 $4,000
Q1 2023

May 11, 2023
SELL
$1.75 - $2.25 $91,847 - $118,089
-52,484 Reduced 10.63%
441,025 $811,000
Q4 2022

Feb 13, 2023
BUY
$1.74 - $3.27 $88,668 - $166,635
50,959 Added 11.51%
493,509 $938,000
Q3 2022

Nov 14, 2022
SELL
$2.04 - $3.76 $375,296 - $691,723
-183,969 Reduced 29.36%
442,550 $947,000
Q2 2022

Aug 11, 2022
SELL
$2.04 - $4.68 $352,999 - $809,822
-173,039 Reduced 21.64%
626,519 $1.77 Million
Q1 2022

May 11, 2022
SELL
$3.52 - $5.46 $182,990 - $283,843
-51,986 Reduced 6.1%
799,558 $3.33 Million
Q4 2021

Feb 10, 2022
SELL
$5.1 - $7.0 $2.55 Million - $3.5 Million
-499,811 Reduced 36.99%
851,544 $4.42 Million
Q3 2021

Nov 12, 2021
BUY
$5.32 - $7.37 $7.19 Million - $9.96 Million
1,351,355 New
1,351,355 $8.85 Million

Others Institutions Holding AUTL

# of Institutions
104
Shares Held
163M
Call Options Held
2.8K
Put Options Held
13.4K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $208M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email